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Available online 10 July 2017Although the majority of late-onset Alzheimer's disease (AD) patients are labeled sporadic, multiple genetic risk
variants have been identified, themost powerful and prevalent of which is the e4 variant of the Apolipoprotein E
(APOE) gene. Here, we generated human induced pluripotent stem cell (hiPSC) lines from the peripheral blood
mononuclear cells (PBMCs) of a clinically diagnosed AD patient [ASUi003-A] and a non-demented control (NDC)
patient [ASUi004-A] homozygous for the APOE4 risk allele. These hiPSCs maintained their original genotype,
expressed pluripotency markers, exhibited a normal karyotype, and retained the ability to differentiate into
cells representative of the three germ layers.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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. This is an open access article underResource utility
Polymorphisms in the Apolipoprotein (APOE) gene have been iden-
tified as the most prevalent of the risk factors associated with sporadic
Alzheimer's disease (AD). As such, hiPSCs with various APOE genotypes
will provide a valuable resource to study themechanisms bywhich this
risk factor contributes to AD onset and progression.Resource details
Genome-wide association studies (GWAS) studies have identified
several risk factors associated with increased probability of sporadic
Alzheimer's disease (SAD) onset (Bettens et al., 2010). Of these risk
factors, polymorphism in the Apolipoprotein E (APOE) gene, a lipo-
protein transporter involved in cholesterol metabolism, is the stron-
gest and most prevalent (Hauser and Ryan, 2013). Compared to
individuals with anAPOE e3/3 genotype (referred to as the ‘risk neutral’
allele), heterozygosity for the e4 allele increases AD risk by 3 fold, and
homozygosity for the e4 allele increases risk up to 12 fold (Wolf et al.,
2013). In this study, we report the generation of hiPSCs from two indi-
viduals from the Arizona APOE Cohort (for which recruitment and en-
rolment strategies have been described previously (Caselli et al.,
2011)) that are homozygous for the APOE e4 allele— a clinically diag-
nosed AD patient (ASUi003-A, Mini-Mental Status Exam [MMSE]
score = 14) who fulfilled published diagnostic criteria (McKhann etthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
ASUi003-A 003 F 70 N/A APOE: 112R/158R Alzheimer's disease
ASUi004-A 004 M 65 N/A APOE: 112R/158R Healthy/non-demented
Fig. 1. Characterization of ASUi003-A and ASUi004-A human induced pluripotent stem cells (hiPSCs).
267N. Brookhouser et al. / Stem Cell Research 25 (2017) 266–269al., 2011) and an age-matched non-demented control patient (NDC;
ASUi004-A, MMSE score = 30) (Table 1).
Peripheral blood mononuclear cells (PBMCs) were reprogrammed
into hiPSCs using the non-integrating CytoTune®-iPS 2.0 Reprogramming
System (Thermo Fisher Scientific). Several clones from each patient were
isolated, expanded and characterized (Fig. 1 and Table 2). The expanded
hiPSC clones displayed a typical pluripotent stem cell morphologyTable 2
Characterization and validation.
Classification Test Result
Morphology Photography Normal
Phenotype Immunocytochemistry Positive s
Flow cytometry OCT4/SSE
Genotype Karyotype (G-banding) and resolution 46XX (AS
46XY (AS
Resolutio
Identity Microsatellite PCR (mPCR) Not perfo
STR analysis 16 Loci
All match
Mutation analysis Sequencing Homozyg
Southern Blot OR WGS Not perfo
Microbiology and virology Mycoplasma Mycoplas
Negative
Differentiation potential Embryoid body Endoderm
SMA, TBX
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C Not perfo
Genotype additional info (OPTIONAL) Blood group genotyping Not perfo
HLA tissue typing Not perfo(Fig. 1A). All expanded clones were confirmed to be negative for myco-
plasma (Supplementary Table 1). Sequencing analysis of the hiPSCs at
theAPOEgene in exon 4 confirmhomozygosity at the e4 allele, identical
to the parental PBMCs [Fig. 1B; Note: Human APOE has three major iso-
forms, ApoE2, ApoE3, andApoE4,whichdiffer by two amino acid substi-
tutions at residues 112 and 158 in exon 4—ApoE2 (Cys112, Cys158),
ApoE3 (Cys112, Arg158), ApoE4 (Arg112, Arg158)]. Expanded clonesData
Fig. 1A
taining for OCT4, NANOG, and SOX2 Fig. 1D
A-4 Double Positive N95% Fig. 1E
Ui003-A)
Ui004-A)
n 450–550
Fig. 1C
rmed
ed
Submitted in archive with journal
ous for Apolipoprotein e4 risk variant Fig. 1B
rmed
ma testing by luminescence Supplementary Table 1
(AFP, EOMES, SOX17), mesoderm (ISL1, MSX1,
3), and ectoderm (B3T, NCAM, PAX6, SOX1)
Fig. 1G and H
rmed
rmed
rmed
268 N. Brookhouser et al. / Stem Cell Research 25 (2017) 266–269maintained a normal euploid karyotype (Fig. 1C). Immunofluorescent
staining (Fig. 1D) and flow cytometry (Fig. 1E) revealed that the
hiPSCs expressed high levels of pluripotency-associated markers
NANOG, OCT4, SOX2, and SSEA-4. Absence of viral transgenes in ex-
panded clones was confirmed by RT-PCR (Fig. 1F). Finally, to verify
pluripotency, hiPSCs were spontaneously differentiated in vitro
through embryoid body (EB) formation. Immunofluorescence (Fig.
1G) and gene expression analysis (Fig. 1H) of EBs revealed downreg-
ulation of pluripotency-associated markers (OCT4, NANOG, SOX2)
and upregulation of genes associated with endoderm (AFP, EOMES,Table 3
Reagent details.
Antibodies used for immunocytochemistry and flow cytometry
Antibody
Pluripotency Markers Mouse anti-OCT4
Mouse anti-NANOG
Goat anti-SOX2
Mouse IgG1 anti-OCT4-PE
Mouse IgG3 anti-SSEA4-APC
Differentiation Markers Rabbit anti-AFP
Mouse-anti SMA
Mouse anti-B3T
Secondary Antibodies Alexa 488 Donkey anti-goat IgG
Alexa 647 Donkey anti-mouse IgG
Alexa 488 Donkey anti-rabbit IgG
Isotype Control Mouse IgG1-PE
Mouse IgG1-APC
Primers
Target
SeV Transgene (RT-PCR) SeV
Pluripotency Markers (qPCR) NANOG
OCT4
SOX2
Germ Layer Markers (qPCR) AFP
EOMES
ISL1
MSX1
NCAM
SOX1
SOX17
TBX3
PAX6
House-Keep Gene (qPCR) 18s
Genotyping (PCR) APOESOX17), mesoderm (ISL1, MSX1, SMA, TBX3), and ectoderm (B3T,
NCAM, PAX6, SOX1).
Materials and methods
Reprogramming of PBMCs
Peripheral blood samples were collected in BD Vacutainer cell prep-
aration tubes and centrifuged for 30 min at 1800 RCF. Isolated PBMCs
were cultured in expansion medium (EM; QBSF-60 [Fisher Scientific]Dilution Company Cat # and RRID
1:50 Santa Cruz, Cat# sc-5279
RRID: 628051
1:50 Santa Cruz, Cat# sc-293121
RRID: 10548762
1:50 Santa Cruz, Cat# sc-17320
RRID: 2286684
1:10 BD Biosciences, Cat# 560186
RRID: 1645331
1:10 R&D Systems, Cat# FAB1435A
RRID: 494994
1:50 Santa Cruz, Cat# sc-15375
RRID: 2223935
1:50 Santa Cruz, Cat# sc-53015
RRID: 628683
1:100 Fitzgerald, Cat# 10R-T136A
RRID: 1289248
1:200 Thermo Fischer, Cat# A11055
RRID: 2534102
1:200 Thermo Fisher, Cat# A31571
RRID: 162542
1:200 Thermo Fisher, Cat# A21206
RRID: 141708
1:10 BD Biosciences, Cat# 559320
RRID: 397218
1:10 R&D Systems, Cat# IC007A
RRID: 952035
Forward/Reverse primer (5′-3′)
GGATCACTAGGTGATATCGAGC
ACCAGACAAGAGTTTAAGAGATATGTATC
CAATGGTGTGACGCAGGGAT
GGACTGTTCCAGGCCTGATT
CAAAGCAGAAACCCTCGTGC
CTCGGACCACATCCTTCTCG
GGATAAGTACACGCTGCCCG
ATGTGCGCGTAACTGTCCAT
AGAGTTGCTAAAGGATACCAGGA
AGGCCAATAGTTTGTCCTCAC
AAATGGGTGACCTGTGGCAAAGC
CTCCTGTCTCATCCAGTGGGAA
GGATTTGGAATGGCATGCGG
CATTTGATCCCGTACAACCTGA
CCCTGGTGCTGTACCCC
GGTCCCTTCAACCTACCTT
AGACCCCATTCCCTCCATCA
TGTGCCCATCCAGAGTCTTT
AATACTGGAGACGAACGCCG
CCCTCGAGCAAAGAAAACGC
GAATCCAGACCTGCACAACG
CTCTGCCTCCTCCACGAAG
ATTTCACAATTCTCGGTGGA
TATAATTCCCCTGCCACGTA
CTTCGCTAATGGGCCAGTGA
TCAGATTCCTATGCTGATTGGTGA
GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
TAAGCTTGGCACGGCTGTCCAAGGA
ACAGAATTGGCCCCGGCCTGGTACAC
269N. Brookhouser et al. / Stem Cell Research 25 (2017) 266–269supplemented with 100 μg/mL Primocin [Fisher Scientific], 1% penicil-
lin/streptomycin [Thermo Fisher], 50 μg/mL ascorbic acid [Sigma],
50 ng/mL SCF [R&D], 10 ng/mL IL-3 [R&D], 2 U/mL EPO [R&D],
40 ng/mL IGF-1 [R&D], 1 μM Dexamethasone [Sigma]). After 9–
12 days of expansion, 2.5 × 105 PBMCs were resuspended in EM and
transferred to a 12 well plate. Sendai viruses (SeV; CytoTune®-iPS 2.0
Reprogramming Kit [Thermo Fisher]) were added at a minimummulti-
plicity of infection (MOI) of 5. Three days after transduction, cells were
cultured on hESC-qualifiedMatrigel® (Corning) in TeSR-E7medium for
7 days, and then switched to TeSR-E8 (E8) medium (STEMCELL Tech-
nologies). After 21 days, individual hiPSC colonies were mechanically
isolated and expanded. After mechanically passaging for the first 3 pas-
sages, hiPSCs were non-enzymatically passaged using ReLeSR™
(STEMCELL Technologies) and cryopreserved. For routine maintenance
and downstream characterization experiments, hiPSCs were passaged
every 4–5 days with Accutase (Thermo Fisher) and 5 μMRho kinase in-
hibitor (Y-27632; Biogems). Mycoplasma testing was performed with
the MycoAlert PLUS kit (Lonza) and the Lucetta™ Luminometer
(Lonza).
Quantitative RT-PCR
RNAwas isolated from cells (NucleoSpin RNA Kit, Clontech) and re-
verse transcription was performed (iScript RT Supermix, Bio-Rad).
Quantitative PCR was performed with SYBR green dye on a Bio-Rad
CFX384 TouchTM Real-Time PCR Detection System. Primer sequences
are provided in Table 3. Gene expression was normalized to 18S rRNA
levels. Relative fold changes in gene expression were calculated using
the 2−ΔΔCt method.
APOE genotyping
Genomic DNAwas isolated from cells using the DNeasy kit (Qiagen).
PCR of APOE exon 4was performed using primers in Table 3. Sanger se-
quencing was performed on PCR products (ASU DNA Core Lab).
Karyotyping and STR analysis
Cytogenetic analysis was performed using standard protocols for G-
banding (Baylor Miraca Genetics Laboratories). Short tandem repeat
(STR) analysis was performed with Promega's PowerPlex® 16 multi-
plex STR system (Cell Line Genetics).
Flow cytometry
Cells were dissociated, fixed, and stained using standard procedures
for flow cytometry. Cells were analysed on an LSR II flow cytometer (BD
Biosciences). Antibodies are listed in Table 3.Immunofluorescence
Cultures were fixed, permeabilized, and stained using standard pro-
cedures for immunofluorescence. Antibodies used are listed in Table 3.
Nucleic acids were stained for DNA with Hoechst 33342 (2 μg/mL; Life
Technologies). Imaging was performed using an EVOS microscope
(Thermo Fisher).In vitro embryoid body (EB) formation
HiPSCs were harvested using ReLeSR™ (StemCell Technologies)
and plated on low attachment plates in E8 medium. The following
day, the media was changed to differentiation medium (DM;
DMEM/F12, 20% FBS, 1% Pen/Strep). After 5 days, EBs were plated
on Matrigel-coated plates and cultured with DM. After 14 days,
cells were fixed, permeabilized, and stained for germ layer markers.
In addition, cells were dissociated using Accutase, RNA was isolated,
and RT-PCR was performed to assess expression of pluripotency and
germ layer markers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2017.07.003.Author disclosure statement
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